Enveda Secures $311M for AI-Powered Nature-Derived Drugs

## Enveda Secures $311M to Bring More Nature-Derived AI Drugs into Clinical Trials Enveda Biosciences, a pioneering AI biotech firm focused on nature-derived drug discovery, has announced the successful closure of a $311 million funding round. This substantial investment has propelled the company's valuation to $2 billion, underscoring growing confidence in its innovative approach to drug development. The capital infusion is earmarked to accelerate Enveda's efforts to advance more of its AI-powered, nature-derived drug candidates into clinical trials. The company leverages its sophisticated AI platform to analyze complex natural compounds, identifying promising drug candidates that can address a wide array of medical conditions. Currently, Enveda is actively testing drugs designed to treat various skin conditions. Furthermore, the firm is developing novel solutions aimed at preserving weight loss after patients cease taking GLP-1 medications, which are commonly used for obesity and type 2 diabetes management. This funding marks a pivotal step for Enveda as it strives to revolutionize drug discovery and deliver impactful new treatments to patients globally.